Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Ashok Raj; Kerry McGowan; Esther Knapp; Jun Zhao; Siddharth Shah

doi:10.7759/cureus.24146

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease

Cureus. 2022 Apr 14;14(4):e24146. doi: 10.7759/cureus.24146. eCollection 2022 Apr.

Authors

Ashok Raj¹, Kerry McGowan¹, Esther Knapp¹, Jun Zhao¹, Siddharth Shah²

Affiliations

¹ Pediatric Hematology and Oncology, University of Louisville, Louisville, USA.
² Pediatric Nephrology, University of Louisville, Louisville, USA.

Abstract

Patients with transfusion-dependent sickle cell disease (SCD) are at risk of iron overload and its complications. Iron overload is a significant risk factor for chronic liver disease in patients who are dependent on hemodialysis secondary to end-stage renal disease (ESRD). Deferasirox is being increasingly used as an iron-chelating agent for the treatment of iron overload in both adults and children. There are limited reports on its use in pediatric patients with ESRD. Here, we discuss the use of deferasirox to treat iron overload in a 15-year-old male with SCD, ESRD from granulomatosis with polyangiitis, and dependent on hemodialysis. We also review the literature on similar uses of deferasirox in adult patients with ESRD.

Keywords: anca; deferasirox; end-stage renal disease; hemodialysis; sickle cell disease.

Publication types

Case Reports